◇AsU launches dual functional health functional food’AsU Immune Vitamin C 2000′
AsU, a health care distribution brand of Hwanin Pharmaceutical, announced on the 24th that it has launched’AsU Immune Vitamin C 2000′, a dual functional health functional food.
This product is a combination of vitamin C, which helps antioxidant, and zinc, which is essential for normal immune function, and features high levels of vitamin C and zinc, which can be easily consumed in one capsule a day.
An AsU official said, “’AsU Immune Vitamin C 2000′ is a product that can help modern people in these days when interest in personal hygiene and immunity has increased due to coronavirus along with cold weather.” “Silicon dioxide, stearic acid It is an honest product with no added magnesium, crystalline cellulose, colorants, sodium caseinate, and HPMC.”
‘AsU Immune Vitamin C 2000’ carefully selected and used premium vitamin C ingredients from UK DSM, a world-class vitamin manufacturer, and contains 2000mg of vitamin C and 8.5mg of zinc in one package, and 2000% of vitamin C and 100 of zinc compared to the daily nutrient standard. It is a product containing %.
Vitamin C is a nutrient recommended for all ages because it is excellent in antioxidant activity and helps improve immunity, prevent aging, relieve stress, and is involved in the synthesis of collagen that makes up connective tissues such as bone, cartilage, and skin. Megados therapy, which consumes high doses of vitamin C, can be expected to increase the efficiency of white blood cells and lymphocytes and increase immunity by combining with other antioxidants.
In addition, zinc is an essential nutrient for normal immune function and cell division, and is an essential nutrient ingredient in these days when interest in personal hygiene and immunity has increased.
AsU Immune Vitamin C 2000 (100 packets/box) can be purchased through online shopping malls.
◇ Ildong Pharmaceutical introduces eco-friendly best practices at UN ESCAP seminar
Ildong Pharmaceutical (CEO Yun Woong-seop) is a company at the’Sustainable Private Sector’ international webinar held through the’SDG Help Desk’ of the United Nations Economic and Social Commission for Asia Pacific (UN ESCAP). It was announced on the 24th that the eco-friendly management of the company was introduced as an excellent case.
The UN Sustainable Development Goals (UN SDGs) Association, who participated in this seminar as a theme presentation and sponsoring organization, noted that Ildong Pharmaceutical and Ildong Holdings’ campaign to reduce particulate matter, and efforts to introduce eco-friendly manufacturing processes, are the Green and Responsible Practices I explained that I received it.
Ildong Pharmaceutical and Ildong Holdings have been working as members of the UN SDGs Association, paying attention to social issues such as the environment. As a result, Ildong Pharmaceutical has been selected as a ‘2020 Global Sustainable Enterprise’ and ‘2020 UN Sustainable Development Goals Management Index (UN SDGBI) No. 1 Group’ hosted by the association.
Last year, Ildong Holdings and Ildong Pharmaceutical signed a special campaign business agreement with the UN SDGs Association to improve fine dust, and participated in fine dust reduction activities by separately manufacturing and supplying campaign masks.
In the case of Ildong Pharmaceutical, while acquiring the international environmental management standard’ISO 14001′ certification for the entire production process, the introduction of the’Green Eco Package’ indicating the packaging material and recycling level of products, etc. We are focusing on eco-friendly management.
The UN SDGs Association said, “The Asia-Pacific region is the most active green market in the world,” and “We plan to actively support Korean companies so that they can enter the related industries and become a major player.”
An official from Ildong Pharmaceutical said, “While strengthening the company’s ESG (environmental, social, governance) management stance, various activities and sustainable development goals (SDGs) promoted by the UN SDGs Association to solve social problems such as climate and environment, etc. I plan to continue to participate in my back.”
◇DM Bio won the Prime Minister’s citation for job creation
DM Bio announced on the 24th that it received the Prime Minister’s citation in the group sector in recognition of its contribution to job creation in the’Government Award for Merit of Job Creation in 2020′. The awards ceremony did not proceed due to social distancing due to Corona 19.
The government award for job creation, organized by the Ministry of Employment and Labor, is a system that discovers and rewards individuals and organizations that have contributed to the creation of good jobs by increasing jobs every year or improving job quality.
DM Bio is a biopharmaceutical company established in collaboration with Dong-A Socio Holdings and Meiji Seika Pharma. The number of employees who were 66 at the time of establishment in 2015 increased 190% to 192 as of July 2020, and continued efforts to provide quality jobs to young talents. The ratio has expanded to 79%. DM Bio’s job creation, efforts to recruit young talent, and various policies implemented to stabilize employment were highly evaluated.
DM Bio continues to make efforts to stabilize employment, and the proportion of regular workers reaches 96.3%. In addition, through open recruitment without any conditions other than job performance capabilities, local youth and women are considered for jobs. Of the total workers, 65% are residents of the Incheon area, and 36% are female workers.
In addition, it contributed to the balance between work and family by expanding the coverage of workplace group insurance to spouses, including support for school expenses and medical expenses through the operation of the in-house worker welfare fund, and providing dormitories and subsidies to new employees without affiliation in Incheon. We are working hard to improve employee welfare.
DM Bio was certified as an excellent company in the fields of wages, work life balance, and employment safety by hiring young talent, stabilizing youth employment, and supporting the establishment of an economic independence base, and was also selected as a youth-friendly small and medium-sized enterprise in 2021.
A DM Bio official said, “DM Bio is providing generous support for the creation of high-quality jobs and for youth and local communities to grow together.” “It is a difficult situation with Corona 19, but we will continue to contribute to the local community while protecting and creating jobs. We will actively participate in the job policy.”
Meanwhile, Dong-A Socio Group is contributing to the serious reduction of youth unemployment through continuous job creation and creating a company that all employees want to attend and work happily.
Dong-A Socio Holdings, Dong-A ST, and Dong-A Pharmaceutical have been selected as family-friendly certification companies that certify that they are exemplary companies that provide support for childbirth and rearing, flexible working system, and creating a family-friendly workplace culture. In particular, Dong-A Pharmaceutical was selected as the number one pharmaceutical company in the pharmaceutical company category in the ‘2020 University Students Consciousness Survey and Corporate Product Preference Survey’ conducted by the Korean University Newspaper.
◇ Daewon Pharmaceutical and Boryeong Pharmaceutical signed a joint promotion contract for two types of’Kanab’ family, a new drug for treating hypertension
Daewon Pharmaceutical (CEO Seung-yeol Baek) announced on the 24th that it has signed a joint promotion contract with Boryeong Pharmaceutical (CEO Ahn Jae-Hyun, Lee Sam-Soo) and a new drug for treating hypertension,’Kannab Family (Akab, Tubero)’.
At the signing ceremony of the joint promotion contract held at Daewon Pharmaceutical’s headquarters on the 23rd, Daewon Pharmaceutical’s Vice Chairman Seung-Yeol Baek and President Tae-Hong Choi, and CEO of Boryeong Pharmaceuticals Jaehyun Ahn and Samsoo Lee attended.
The two products that will be jointly sold are’Akab Tablet’ and’Tubero Tablet’, a combination drug of’Kannab’, an existing high blood pressure treatment, plus a treatment for hyperlipidemia, among Boryeong Pharmaceutical’s representative blockbuster new drug’Kannab’ family.
‘Tubero’ is a product that improves the patient’s medication convenience by combining’Pimasartan’, an ingredient of Kanab, a new hypertension drug, and’Rosuvastatin’, an ingredient for treating hyperlipidemia, and was launched in 2016, and’Akab’ is Kanab. It is a new product released this year as a combination of’Atorvastatin’, which is used as a treatment for hyperlipidemia, with’pimasartan’.
Since many hypertensive patients have hyperlipidemia, the proportion of combination drugs in the hypertension treatment market is constantly increasing.
With this contract, the distribution, sales and marketing of’Tubero’ to all domestic hospitals will be handled by Daewon Pharmaceutical, and the distribution of’Arkave’ will be conducted by Daewon Pharmaceutical, and the sales and marketing will be jointly conducted by the two companies.
Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical said, “The Kanab Family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model of a new drug made in Korea.” “Through this cooperation, it is expected to establish itself as another success model for collaboration between domestic companies. We look forward to helping more patients improve their quality of life.”
Daewon Pharmaceutical Vice Chairman Seung-Yeol Baek said, “Based on Daewon Pharmaceutical’s differentiated marketing capabilities and sales know-how, we will strive to expand the market share of the’Kannab’ brand so that more hypertension and hyperlipidemia patients can benefit from the treatment benefits of the innovative new drug, Kanab Family. “We will continue to expand our product portfolio in the area of chronic diseases in the future so that we can contribute to improving the health of the people.”
Meanwhile, according to the drug research institute UBIST, the domestic hypertension/hyperlipidemia combination market is estimated to be about KRW 114.3 billion by the third quarter of this year. The’Kannab’ family recorded a cumulative prescription amount of 94.3 billion won until November of this year, which is a strong mark of 100 billion won this year.
◇ Hanmi Pharm, differentiated COVID-19 quarantine’attention’
Hanmi Pharm is preemptively implementing differentiated quarantine measures to prevent the spread of Corona 19 among employees.
Hanmi Pharm (CEO Jong-soo Woo and Se-chang Kwon) is the only pharmaceutical company in Korea to preemptively implement the’three step’ guidelines for social distancing, and from the 21st, all employees, excluding essential personnel, are working from home.
In addition, Hanmi Pharm ordered about 5,000 nasal sprays of’Hanmi Cold Mask’, a respiratory virus blocker that sprays on the nose, which it recently launched, to all employees and to do their best in personal quarantine.
Since February of this year, Hanmi Pharm has also been providing KF94 masks, 5 per employee each week, and has mandated hand sanitizer and mouthwash’Care Gargle’ in the offices and toilets of employees. The company explained that the spread of the virus can be greatly reduced just by thoroughly closing the nose and mouth, which are the main channels of virus infection, and keeping hands and mouth clean.
Along with this, Hanmi Pharm has distributed a self-developed Corona 19 self-diagnosis app to all employees since the beginning of this year, and has taken measures so that they can only go to work by checking their physical condition through this app every morning. Passing through thermal imaging cameras, individual thermometers, hand disinfection, etc. are always in operation as basic matters.
In particular, Hanmi Pharmaceutical has established measures to cope with the spread of Corona 19 in 0.5 steps, and transparently informs employees of the situation that changes in real time. Since the beginning of this year, the company has been operating an emergency control room in the head office and managing measures to prevent the spread of the virus by employees in real time.
“We have a strict awareness that anyone can be infected with the virus in a situation where Corona 19 is rapidly spreading,” said Hanmi Pharm’s CEO, Jongsoo Woo. “We will continue to take preemptive and intensive measures for the health of our employees quickly.” Said.
◇Huons-Ripak, completed 1/2a clinical trial of’superficial bladder cancer treatment’ in the US
Huons (CEO Ki-an Eom) is jointly researching and developing a superficial (non-invasive) bladder cancer anti-cancer drug’LiPax’ (LiPax, TSD-001), which is being developed in collaboration with’LIPAC Oncology LLC’, an American anticancer drug company. It was announced on the 24th that it had successfully ended clinical 1/2a in the United States.
This clinical trial 1/2a was conducted to confirm the anticancer effect and safety for patients with low grade superficial bladder cancer (stage Ta) of’Lipax (TSD-001)’, an anticancer drug injected into the bladder after bladder tumor resection. .
Both companies revealed that they had an average of 63% Marker Lesion Response Rate through this clinical 1/2a Final Result Report (CSR), which was conducted in patients who had recurred despite treatment of superficial bladder cancer, which was in the Ta stage stage. He explained that it indicates the possibility of preventing recurrence of low-grade superficial bladder cancer.
In terms of safety, it also revealed that there was no change in the quality of life of patients related to urinary tract health, and there was no serious adverse reactions of grade 3 or higher and systemic exposure to the active ingredient’paclitaxel’.
Ripak CEO TR Thirucote said, “With the successful termination of 1/2a, we achieved a major development milestone with Huons.” “Based on the 1/2a clinical CSR, we entered phase 2b/3 clinical trials with the FDA in January. We plan to hold a meeting for the company.
“Non-invasive superficial bladder cancer accounts for as much as 75% of all bladder cancer patients,” said Dr. Michael Oefelein, Chief Clinical Officer of Ripak. “This month, it is very difficult to treat and has a high recurrence rate.” As previously announced at the American Society of Urology and Oncology, the efficacy and safety of combined treatment of bladder tumor resection (TURBT) and’Lipax’ is a new treatment option that can improve the quality of life of superficial bladder cancer patients around the world. ”
Huons CEO Gi-an Eom said, “In clinical 1/2a, we confirmed the anticancer effect and safety beyond expectations, and according to the contract, we also paid the first milestone to Ripak.” “Huons’ Lipax is not only used for superficial bladder cancer, but , It is expected that there will be a potential for expansion into treatments such as ovarian cancer, mesothelioma, and malignant pleural effusion caused by breast cancer, and we plan to continue working with Ripac in the future.”
Meanwhile, in September last year, Huons secured exclusive rights for all indications of LiPax and LiPax (TSD-001), and the two companies are conducting joint research and development aiming at the first superficial bladder cancer treatment that is approved by the US FDA. In the middle.
Copyright © Medical News Unauthorized reproduction and redistribution prohibited